MedTrace Logo

START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer

NCT05492682 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2026-05-12

No results posted yet for this study

Summary

This study is being conducted to explore the immunological mechanism of action of Peptide-coated Conditionally Replicating Adenovirus-1 (PeptiCRAd-1) plus Checkpoint inhibitor (CPI) therapy in multiple cancer types, as well as to obtain early information on the safety of this combination therapy.

Conditions

Interventions

DRUG

PeptiCRAd-1

All patients will receive PeptiCRAd-1.

DRUG

Cyclophosphamide

All patients will be pre-treated with one single dose of Cyclophosphamide.

DRUG

Pembrolizumab

All patients will receive 6 doses of Pembrolizumab within the study.

Sponsors & Collaborators

  • Valo Therapeutics Oy

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-02
Primary Completion
2027-04-30
Completion
2027-05-31

Countries

  • Germany
  • Italy

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05492682 on ClinicalTrials.gov